ReviewJournal of clinical medicine2021
Female Oncofertility: Current Understandings, Therapeutic Approaches, Controversies, and Future Perspectives.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Fertility discussions and concerns in childhood cancer survivors, a systematic review for updated practice.Cancer medicine · 2023Pooled it
- The role of patient age in fertility preservation among women with breast cancer: biological mechanisms and clinical implications.Journal of assisted reproduction and genetics · 2026Review
- The role of patient age in fertility preservation among women with breast cancer: biological mechanisms and clinical implications.Journal of assisted reproduction and genetics · 2026Review
- Indole-3-carbinol alleviates cisplatin-induced ovarian damage by inhibiting ovarian fibrosis through the TGF-β1/Smad pathway.Journal of ovarian research · 2026Article
- Evaluating Trends in Fertility Counseling among Reproductive-Age Patients with Breast Cancer.Annals of surgical oncology · 2025Article
- Icariin inhibits cisplatin-induced ovarian toxicity via modulating NF-κB and PTEN/AKT/mTOR/AMPK axis.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Ovarian tissue cryopreservation and transplantation as a natural means to delay menopause.Archives of gynecology and obstetrics · 2024Review
- Fertility Preservation in BRCA1/2 Germline Mutation Carriers: An Overview.Life (Basel, Switzerland) · 2024Review
- Fertility Preservation in the Era of Immuno-Oncology: Lights and Shadows.Journal of personalized medicine · 2024Review
- The Impact of Systemic Oncological Treatments on the Fertility of Adolescents and Young Adults-A Systematic Review.Life (Basel, Switzerland) · 2023Review
- Germline stem cells in human.Signal transduction and targeted therapy · 2022Review
- Signaling pathway intervention in premature ovarian failure.Frontiers in medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in early detection and oncological therapies have ameliorated the survival rate of young cancer patients. Yet, ovarian impairment induced by chemotherapy and radiotherapy is still a challenging issue. This review, based on clinical and lab-based studies, summarizes the evidence of gonadotoxicity of chemoradiotherapy, the recent approaches, ongoing controversies, and future perspectives of fertility preservation (FP) in female patients who have experienced chemo- or radio-therapy. Existing data indicate that chemotherapeutic agents induce DNA alterations and massive follicle activation via the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway. Meanwhile, the radiation causes ionizing damage, leading to germ cell loss. In addition to the well-established methods, numerous therapeutic approaches have been suggested, including minimizing the follicle loss in cryopreserved ovarian grafts after transplantation, in vitro activation or in vitro growing of follicles, artificial ovarian development, or fertoprotective adjuvant to prevent ovarian damage from chemotherapy. Some reports have revealed positive outcomes from these therapies, whereas others have demonstrated conflictions. Future perspectives are improving the live birth rate of FP, especially in patients with adverse ovarian reserve, eliminating the risk of malignancy reintroducing, and increasing society's awareness of FP importance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.